1349 — Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co Share Price
- HK$2.23bn
- HK$914.63m
- CNY850.73m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.88 | ||
Price to Tang. Book | 0.91 | ||
Price to Free Cashflow | 9.52 | ||
Price to Sales | 2.55 | ||
EV to EBITDA | 8.93 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 4% | ||
Return on Equity | 4.42% | ||
Operating Margin | 11.71% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 1,029.29 | 833.8 | 1,140.31 | 1,031.16 | 850.73 | n/a | n/a | 2.78% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +88.44 | -31.63 | +22.19 | -34.3 | -18.58 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd is a China-based company mainly engaged in research and development, manufacturing and marketing of biomedicine. The Company's products include aminolevulinic acid hydrochloride topical powder (trade name: ALA) and hemporfin or injection (trade name: FuMeiDa), and doxorubicin hydrochloride liposome injection (trade name: LIBOd), among others. Its products are mainly used for skin venereal disease treatment and anti-tumor treatment. The Company conducts its businesses in the domestic market.
Directors
- Hai Bo Wang CHM (59)
- Yan Xue CFO (33)
- Da Jun Zhao CCO (49)
- Yi Min Gan DGM (52)
- Jun Li DGM (46)
- Xiao Lin Yang DGM (52)
- Yong Su EDR (55)
- Ying Ke NED (46)
- Bo Shen NED (48)
- Xiao Yang Yu NED (63)
- Yiu Kin Lam NID (66)
- Qing Xu NID (55)
- Chun Bao Yang NID (50)
- Zhong Hui Zhou NID (72)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- November 11th, 1996
- Public Since
- August 13th, 2002
- No. of Shareholders
- 21,686
- No. of Employees
- 948
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Shares in Issue
- 1,036,572,100
- Address
- Zhangjiang Hi-tech Park, SHANGHAI, 201210
- Web
- http://www.fd-zj.com
- Phone
- +86 2158553583
- Contact
- Yan Xue
- Auditors
- PricewaterhouseCoopers Zhong Tian LLP
Upcoming Events for 1349
Similar to 1349
3D Medicines
Stock Exchange of Hong Kong Limited
3SBio
Stock Exchange of Hong Kong Limited
AIM Vaccine Co
Stock Exchange of Hong Kong Limited
Ascletis Pharma
Stock Exchange of Hong Kong Limited
Asymchem Laboratories Tianjin Co
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:09 UTC, shares in Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co are trading at HK$2.15. This share price information is delayed by 15 minutes.
Shares in Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co last closed at HK$2.15 and the price had moved by -31.53% over the past 365 days. In terms of relative price strength the Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co share price has underperformed the FTSE Developed Asia Pacific Index by -32.06% over the past year.
There is no consensus recommendation for this security.
The Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co dividend yield is 3.51% based on the trailing twelve month period.
Last year, Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co paid a total dividend of CNY0.07, and it currently has a trailing dividend yield of 3.51%.Looking ahead, shares in Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co are due to go ex-dividend on 2024-07-04 and the next dividend pay date is 2024-08-26.
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co are due to go ex-dividend on 2024-07-04 and the next dividend pay date is 2024-08-26. The historic dividend yield on Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co shares is currently 3.51%.
To buy shares in Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$2.15, shares in Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co had a market capitalisation of HK$2.23bn.
Here are the trading details for Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 1349
Based on an overall assessment of its quality, value and momentum Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -19.25%.
As of the last closing price of HK$2.15, shares in Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co were trading -11.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$2.15.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Shanghai Fudan-zhangjiang Bio-Pharmaceutical Co's management team is headed by:
- Hai Bo Wang - CHM
- Yan Xue - CFO
- Da Jun Zhao - CCO
- Yi Min Gan - DGM
- Jun Li - DGM
- Xiao Lin Yang - DGM
- Yong Su - EDR
- Ying Ke - NED
- Bo Shen - NED
- Xiao Yang Yu - NED
- Yiu Kin Lam - NID
- Qing Xu - NID
- Chun Bao Yang - NID
- Zhong Hui Zhou - NID